Effect of probucol on serum lipids, atherosclerosis and toxicology in fat-fed LDL receptor deficient mice

Atherosclerosis

Volumn 141, Issue 2, 1998, Pages 237-247

  Benson, G Martin ^a   Schiffelers, Raymond ^a   Nicols, Charlotte ^a   Latcham, Judy ^a   Vidgeon Hart, Martin ^a   Toseland, C D Nigel ^a   Suckling, Keith E ^a   Groot, Pieter H E ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

LDL receptor; Lipidosis; Mice; Probucol; Toxicology

Indexed keywords

LIPID; PROBUCOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL DIET; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; GENETIC RECOMBINATION; INFLAMMATORY CELL; LIPID BLOOD LEVEL; LIPID COMPOSITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR DENSITY; RECEPTOR GENE;

ANIMALS; ANTICHOLESTEREMIC AGENTS; AORTA; ARTERIOSCLEROSIS; CHOLESTEROL; DIETARY FATS; FEMALE; LIPIDS; MICE; PROBUCOL; RECEPTORS, LDL; TRIGLYCERIDES;

EID: 0032401620     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(98)00177-4     Document Type: Article

References (28)

1. Hobbs H.H., Brown M.S., Goldstein J.L. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum. Mutat. 1:1992;445-466.
2. Watanabe Y., Ito T., Shiomi M. The effect of selective breeding on the development of coronary atherosclerosis in WHHL rabbits. Atherosclerosis. 56:1985;71-79.
3. Scanu A.M., Khalil A., Neven L., Tidore M., Dawson G., Pfaffinger D., Jackson E., Carey K.D., Mcgill H.C., Fless G.M. Genetically determined hypercholesterolemia in a rhesus monkey family due to a deficiency of the LDL receptor. J. Lipid. Res. 29:1988;1671-1681.
4. Ishibashi S., Brown M.S., Goldstein J.L., Gerard R.D., Hammer R.E., Herz J. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92:1993;883-893.
5. Ishibashi S., Goldstein J.L., Brown M.S., Herz J., Burns D.K. Massive xanthomatosis and atherosclerosis in cholesterol-fed low density lipoprotein receptor-negative mice. J. Clin. Invest. 93:1994;1885-1893.
6. Palinski W., Tangirala R.K., Miller E., Young S.G., Witztum J.L. Increased autoantibody titers against epitopes of oxidised LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15:1995;1569-1576.
7. Neuworth M.B., Laufer R.J., Barnhart J.W., Sefranka J.A., McIntosh D.D. Synthesis and hypocholesterolemic activity of alkylidenedithio bisphenols. J. Med. Chem. 13:1970;722-725.
8. Barnhart J.W., Rytter D.J., Molello J.A. An overview of the biochemical pharmacology of probucol. Lipids. 12:1977;29-33.
9. Tomikawa M., Nakayasu T., Tawara K., Abiko Y. Effect of probucol on serum lipoprotein levels in normal and dyslipoproteinemic mice. Atherosclerosis. 40:1981;101-113.
10. Tawara K., Tomikawa M., Abiko Y. Mode of action of probucol in reducing serum cholesterol in mice. Jpn. J. Pharmacol. 40:1986;123-133.
11. Yamaguchi Y., Kitagawa S., Imaizumi N., Kunitomo M., Fujiwara M. Enhancement of aortic cholesterol deposition by dietary linoleic acid in cholesterol-fed mice: an animal model for primary screening of antiatherosclerotic agents. J. Pharm. Tox. Methods. 30:1993;169-175.
12. Zhang S.H., Reddick R.L., Avdievich E., Surles L.K., Jones R.G., Reynolds J.B., Quarfordt S.H., Maeda N. Paradoxical enhancement of atherosclerosis by probucol treatment in apolipoprotein E-deficient mice. J. Clin. Invest. 99:1997;2858-2866.
13. Jackson R.L., Barnhart R.L., Mao S.J.T. Probucol and its mechanisms for reducing atherosclerosis. Adv. Exp. Med. Biol. 285:1991;367-372.
14. Buckley M.M.-T., Goa K.L., Price A.H., Brogden R.N. Probucol - A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia. Drugs. 37:1989;761-800.
15. Berliner J.A., Heinecke J.W. The role of oxidised lipoproteins in atherosclerosis. Free. Radic. Biol. Med. 20:1996;707-727.
16. Marshall F.N. Pharmacology and toxicology of probucol. Artery. 10:1982;7-21.
17. Lebeau J.E. Toxicologie animale du probucol. La. Nouvelle. Presse. Médicale. 9:1980;3001-3004.
18. Nishina PM, Verstuyft, Paigen B. Synthetic low and high fat diets for the study of atherosclerosis in the mouse. J Lipid Res 1990; 31:859-869.
19. Hennes U., Gross W., Edelmann A. Changes of lipoprotein patterns in hamsters under different metabolic states analyzed following separation by micropreparative chromatography on SMART™ system from multiple micro plasma samplings. Sci. Tools. 36:1992;10-12.
20. Paigen B., Morrow A., Holmes P.A., Mitchell D., Williams R.A. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68:1987;231-240.
21. Groot P.H.E., van Vlijmen B.J.M., Benson G.M., Hofker M.H., Schiffelers R., Vidgeon-Hart M., Havekes L.M. Quantitative assessment of aortic atherosclerosis in APOE*3 Leiden transgenic mice and its relationship to serum cholesterol exposure. Arterioscler. Thromb. Vasc. Biol. 16:1996;926-933.
22. Carew T.E., Schwenke D.C., Steinberg D. Anti-atherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. Proc. Natl. Acad. Sci. USA. 84:1987;7725-7729.
23. Kita T., Nagano Y., Yokode M., Ishii K., Kume N., Ooshima A., Yoshida H., Kawai C. Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. Proc. Natl. Acad. Sci. USA. 84:1987;5928-5931.
24. Eder H.A. Effect of diet on the transport of probucol in monkeys. Artery. 10:1982;105-107.
25. Yamamoto K., Fukuda N., Shiroi S., Shiotsuki Y., Nagata Y., Tani T., Sakai T. Effects of dietary fat levels on the absorption and tissue accumulation of probucol in the rat. Arzneimittelforschung. 44:1994;1059-1062.
26. Nakamura T., Ueyama Y., Funahashi T., Yamashita S., Takemura K.K., Kubo M., Yamada K., Matsuzawa Y. Non-macrophage-related accumulation of cholesterol during probucol treatment in familial hypercholesterolemia: report of two cases. Atherosclerosis. 92:1992;193-202.
27. Dujovne C.A., Atkins F., Wong B., DeCoursey S., Krehbiel P., Chernoff S.B. Electrocardiographic effects of probucol. A controlled prospective clinical trial. Eur. J. Clin. Pharmacol. 26:1984;735-739.
28. Ohya Y., Kumamoto K., Abe I., Tsubota Y., Fujishima M. Factors related to Q-T interval prolongation during probucol treatment. Eur. J. Clin. Pharmacol. 45:1993;47-52.